151 related articles for article (PubMed ID: 35383310)
1. Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre.
Shukla AG; Vaidya S; Yaghy A; Di Nicola M; Kaliki S; Fulco E; Myers JS; Shields JA; Shields CL
Eye (Lond); 2023 Apr; 37(5):938-946. PubMed ID: 35383310
[TBL] [Abstract][Full Text] [Related]
2. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with elevated intraocular pressure in eyes with iris melanoma.
Shields CL; Materin MA; Shields JA; Gershenbaum E; Singh AD; Smith A
Br J Ophthalmol; 2001 Jun; 85(6):666-9. PubMed ID: 11371484
[TBL] [Abstract][Full Text] [Related]
4. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
[TBL] [Abstract][Full Text] [Related]
5. Iris melanoma: features and prognosis in 317 children and adults.
Shields CL; Kaliki S; Shah SU; Luo W; Furuta M; Shields JA
J AAPOS; 2012 Feb; 16(1):10-6. PubMed ID: 22370659
[TBL] [Abstract][Full Text] [Related]
6. Diffuse iris melanoma: a report of 25 cases.
Demirci H; Shields CL; Shields JA; Eagle RC; Honavar SG
Ophthalmology; 2002 Aug; 109(8):1553-60. PubMed ID: 12153810
[TBL] [Abstract][Full Text] [Related]
7. Iris melanoma outcomes based on the Cancer Genome Atlas (TCGA) classification in 78 consecutive patients.
Cherkas E; Negretti GS; Zeiger JS; Shields CL
Ophthalmic Genet; 2022 Dec; 43(6):736-741. PubMed ID: 36326016
[TBL] [Abstract][Full Text] [Related]
8. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.
Shah SU; Shields CL; Bianciotto C; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2012 Apr; 119(4):838-842.e2. PubMed ID: 22133794
[TBL] [Abstract][Full Text] [Related]
9. Iris melanoma: risk factors for metastasis in 169 consecutive patients.
Shields CL; Shields JA; Materin M; Gershenbaum E; Singh AD; Smith A
Ophthalmology; 2001 Jan; 108(1):172-8. PubMed ID: 11150284
[TBL] [Abstract][Full Text] [Related]
10. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes.
Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM
Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876
[TBL] [Abstract][Full Text] [Related]
11. Secondary Glaucoma due to Iridescent Crystalline Particles Masquerading as Refractory Hypertensive Uveitis in an Eye With Irradiated Iris Melanoma.
Chahal R; Mohite AA; Heimann H; Bansal A
J Glaucoma; 2018 Apr; 27(4):385-388. PubMed ID: 29394206
[TBL] [Abstract][Full Text] [Related]
12. Melanomalytic glaucoma secondary to iris melanoma.
Ajamil Rodanés S; García-Álvarez C; Saornil Alvarez MA; López-Lara F; Frutos Baraja JM; Quiñones M
Arch Soc Esp Oftalmol; 2017 Aug; 92(8):379-381. PubMed ID: 27746064
[TBL] [Abstract][Full Text] [Related]
13. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications.
Shields CL; Naseripour M; Shields JA; Freire J; Cater J
Am J Ophthalmol; 2003 May; 135(5):648-56. PubMed ID: 12719072
[TBL] [Abstract][Full Text] [Related]
14. Proton beam radiotherapy of diffuse iris melanoma in 54 patients.
Willerding GD; Cordini D; Hackl C; Karle B; Lakotka N; Foerster MH; Bechrakis NN; Heufelder J; Moser L; Joussen AM
Br J Ophthalmol; 2015 Jun; 99(6):812-6. PubMed ID: 25505288
[TBL] [Abstract][Full Text] [Related]
15. Side Effects of Proton Beam Radiotherapy Treatment on Iris Melanoma.
Eibenberger K; Heimann H; Gatchalian L; Kacperek A; Hussain R
Ophthalmology; 2023 Sep; 130(9):958-965. PubMed ID: 37169262
[TBL] [Abstract][Full Text] [Related]
16. Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy.
Sharkawi E; Oleszczuk JD; Bergin C; Zografos L
Br J Ophthalmol; 2012 Aug; 96(8):1104-7. PubMed ID: 22628537
[TBL] [Abstract][Full Text] [Related]
17. [Iris melanoma in a child].
Griščíková L; Autrata R; Pramuková K; Mlčák P; Marešová K
Cesk Slov Oftalmol; 2016; 72(5):191-194. PubMed ID: 28224806
[TBL] [Abstract][Full Text] [Related]
18. Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors.
Kim EA; Salazar D; McCannel CA; Kamrava M; Demanes DJ; Lamb J; Caprioli J; McCannel TA
J Glaucoma; 2020 Jan; 29(1):1-10. PubMed ID: 31688338
[TBL] [Abstract][Full Text] [Related]
19. Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.
Riechardt AI; Karle B; Cordini D; Heufelder J; Budach V; Joussen AM; Gollrad J
Strahlenther Onkol; 2017 Nov; 193(11):943-950. PubMed ID: 28631017
[TBL] [Abstract][Full Text] [Related]
20. Intraocular Pressure Spike Following Stand-Alone Phacoemulsification in the IRIS® Registry (Intelligent Research in Sight).
Lidder AK; Vanner EA; Chang TC; Lum F; Rothman AL
Ophthalmology; 2024 Jan; ():. PubMed ID: 38246424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
